Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention
Recruiting
N/A
Interventional Study
Ischemia, Myocardial
Coronary Artery Disease
Percutaneous Coronary Intervention (PCI)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3,150 (estimated)
- Sponsor
- Odense University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents
Exclusion Criteria:
* Age \< 18 years
* Not able to consent to study participating (eg. intubated patients)
* Unstable circuit or in cardiogenic shock and therefore no…
Contacts